Axsome Therapeutics holder plans 10,000-share sale

Mark Jacobson files a Rule 144 notice to sell 10,000 AXSM shares via a Rule 10b5-1 selling plan.

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) discloses a planned sale of 10,000 shares of Class A common stock for the account of Mark Jacobson through Goldman Sachs & Co. LLC under Rule 144. The notice estimates an aggregate market value of about $2,083,500 and lists approximately 52,380,818 shares outstanding.

The shares were acquired on March 19, 2019 as compensation via stock options and are to be sold via a cashless exercise / same-day sale. The sales are made pursuant to a selling plan dated June 2, 2026 intended to comply with Rule 10b5-1(c), with an expected sale date around September 3, 2026.

Key Figures

Shares to be sold: 10,000 shares Estimated aggregate market value: $2,083,500 Shares outstanding: 52,380,818 shares +3 more

6 metrics

Shares to be sold 10,000 shares Class A common stock under Rule 144 for Mark Jacobson

Estimated aggregate market value $2,083,500 Planned Rule 144 sale of 10,000 AXSM shares

Shares outstanding 52,380,818 shares Axsome Therapeutics Class A common stock outstanding listed in the notice

Plan date June 2, 2026 Date of selling plan intended to comply with Rule 10b5-1(c)

Approximate sale date September 3, 2026 Expected date for the Rule 144 share sale

Option grant / acquisition date March 19, 2019 Date shares were acquired as compensation via stock options

Key Terms

Rule 144, Rule 10b5-1(c), cashless exercise / same-day sale, selling plan

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"selling plan dated 6/2/2026 that is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

cashless exercise / same-day sale financial

"Compensation -- Cashless exercise / same-day sale"

selling plan financial

"made in connection with a selling plan dated 6/2/2026"

FAQ

What does the Form 144 filing disclose for Axsome Therapeutics, Inc. (AXSM)?

It discloses a planned sale of 10,000 shares of Axsome Therapeutics Class A common stock for the account of Mark Jacobson under Rule 144, with Goldman Sachs & Co. LLC as broker and an estimated value of about $2,083,500.

Who is selling AXSM shares and through which broker?

The notice is for sales for the account of Mark Jacobson, with Goldman Sachs & Co. LLC listed as the broker for the transaction in Axsome Therapeutics, Inc. Class A common stock.

How many Axsome Therapeutics (AXSM) shares are planned to be sold and at what value?

The plan covers 10,000 shares of Axsome Therapeutics Class A common stock, with an estimated aggregate market value of approximately $2,083,500 as stated in the filing.

When were the AXSM shares acquired and how will they be sold?

The shares were acquired on March 19, 2019 as compensation via stock options and are to be sold through a cashless exercise / same-day sale, according to the Form 144 disclosure.

What trading plan governs this AXSM share sale?

The sales are made in connection with a selling plan dated June 2, 2026 that is stated to be intended to comply with Rule 10b5-1(c), providing a pre-arranged framework for the transactions.

How many Axsome Therapeutics (AXSM) shares are outstanding according to the notice?

The notice lists approximately 52,380,818 shares of Axsome Therapeutics Class A common stock as outstanding in connection with the Rule 144 sale disclosure.

What is the expected timing of the planned AXSM share sale?

The filing indicates an approximate sale date of September 3, 2026 for the 10,000 Axsome Therapeutics Class A common shares covered by the Form 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:50 PM Accepted by SEC EDGAR 09/03/2026 - 05:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001805812
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	One World Trade Center 29th Floor New York NEW YORK 10007
Phone	1-212-332-3241
Name of Person for Whose Account the Securities are To Be Sold	Mark Jacobson
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	10000	2083500	52380818	09/03/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	03/19/2019	Acquired as compensation -- Stock Options	Issuer			10000	03/19/2019	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 6/2/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	09/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Mark Jacobson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)